Edition:
United Kingdom

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

13.86EUR
4:34pm GMT
Change (% chg)

€-0.39 (-2.74%)
Prev Close
€14.25
Open
€14.21
Day's High
€14.32
Day's Low
€13.86
Volume
105,187
Avg. Vol
427,886
52-wk High
€44.20
52-wk Low
€7.59

Latest Key Developments (Source: Significant Developments)

DBV Technologies FY Net Loss Widens To 166.1 Million Euros
Tuesday, 5 Mar 2019 

March 6(Reuters) - DBV TECHNOLOGIES SA ::REPORTED ON TUESDAY FY SALES AND MARKETING EXPENSES EUR 32.2 MLN VS EUR 15.8 MLN YR AGO .CASH AND CASH EQUIVALENTS AS OF DEC 31 2018 EUR 122.8 MLN VS EUR 137.9 MLN AS OF DEC 31 2017.FY OPERATING INCOME EUR 14.5 MLN VS EUR 11.9 MLN YR AGO.FY NET LOSS EUR 166.1 MLN VS LOSS OF EUR 147.7 MLN YR AGO."WE BELIEVE OUR CASH ON HAND TODAY WILL BRING US INTO Q4 2019, PROVIDING US WITH SUFFICIENT CASH TO MEET OUR KEY OBJECTIVES THIS YEAR, INCLUDING RESUBMITTING OUR BLA FOR VIASKIN PEANUT" - CEO.  Full Article

DBV Technologies' Viaskin Peanut Detailed Phase III Trial Results In Journal Of American Medical Association
Friday, 22 Feb 2019 

Feb 22 (Reuters) - DBV TECHNOLOGIES SA ::62.6% OF PATIENTS RECEIVING VIASKIN PEANUT SHOWED AN INCREASE IN THEIR ELICITING DOSE AT 12 MONTHS OF TREATMENT.ANNOUNCES PUBLICATION OF DETAILED PHASE III TRIAL RESULTS EVALUATING VIASKIN PEANUT IN JOURNAL OF AMERICAN MEDICAL ASSOCIATION.LOW DISCONTINUATION RATES IN VIASKIN PEANUT ARM DUE TO TREATMENT-EMERGENT ADVERSE EVENTS (1.7%) WERE EXPERIENCED IN TRIAL.  Full Article

DBV Technologies To Resubmit Biologics License Application For Viaskin Peanut In Q3 2019
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - DBV TECHNOLOGIES ::ANNOUNCED ON WEDNESDAY UPDATE ON REGULATORY STATUS OF VIASKIN PEANUT FOR THE TREATMENT OF PEANUT-ALLERGIC CHILDREN 4 TO 11 YEARS OF AGE.RESUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE FDA FOR VIASKIN PEANUT ANTICIPATED IN Q3 2019.  Full Article

DBV Technologies Provides Update On Viaskin Peanut For Children Four To 11 Years Of Age
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - DBV Technologies SA ::DBV TECHNOLOGIES: DBV TECHNOLOGIES PROVIDES UPDATE ON VIASKIN PEANUT FOR CHILDREN FOUR TO 11 YEARS OF AGE.DBV TECHNOLOGIES SA-VIASKIN PEANUT BLA WITHDRAWN POST DISCUSSIONS WITH FDA REGARDING INSUFFICIENT DATA ON MANUFACTURING PROCEDURES & QUALITY CONTROLS.DBV TECHNOLOGIES SA - ANTICIPATES THAT ALL ONGOING CLINICAL TRIALS WITH VIASKIN PEANUT WILL CONTINUE AS PLANNED.DBV TECHNOLOGIES SA - FDA DID NOT CITE CONCERNS RELATED TO SAFETY OR EFFICACY OF VIASKIN PEANUT IN BLA.DBV TECHNOLOGIES SA - CO TO WORK WITH FDA TO PURSUE RESUBMISSION AS QUICKLY AS POSSIBLE.  Full Article

DBV Technologies Presents Data At ACAAI 2018 For Treatment Of Peanut-Allergic Children
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - DBV TECHNOLOGIES SA ::REG-DBV TECHNOLOGIES PRESENTS DATA AT ACAAI 2018 ON INVESTIGATIONAL VIASKIN PEANUT FOR THE TREATMENT OF PEANUT-ALLERGIC CHILDREN.NEW DATA SHOW THAT WITH VIASKIN PEANUT A MAJORITY OF PATIENTS EXPERIENCE AN INCREASE IN PEANUT THRESHOLD REACTIVITY AFTER FIRST 12 MONTHS OF TREATMENT.THREE ORAL PRESENTATIONS HIGHLIGHTED ANALYSES FROM PEPITES PHASE III STUDY.IN PEPITES STUDY, A STATISTICALLY SIGNIFICANT HIGHER RATE OF RESPONDERS WAS OBSERVED WITH VIASKIN PEANUT 250 ΜG COMPARED TO PLACEBO AFTER 12 MONTHS OF TREATMENT.SIGNIFICANT CHANGES IN PEANUT-SPECIFIC AND PEANUT-COMPONENT IGG4 LEVELS WERE OBSERVED AS EARLY AS IN FIRST 3 MONTHS OF TREATMENT WITH VIASKIN PEANUT 250 ΜG (P<0.001).  Full Article

DBV Reports Cash And Cash Equivalents Of 153.9 Million Euros As Of September 30
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - DBV TECHNOLOGIES SA ::REG-DBV TECHNOLOGIES REPORTS SEPTEMBER 30, 2018 CASH POSITION.CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2018, WERE EUR 153.9 MILLION.  Full Article

DBV Technologies Announces Part B Of Phase III Study In Peanut-Allergic Toddlers
Friday, 26 Oct 2018 

Oct 26 (Reuters) - DBV TECHNOLOGIES SA ::REG-DBV TECHNOLOGIES ANNOUNCES INITIATION OF PART B OF PHASE III STUDY IN PEANUT-ALLERGIC TODDLERS.STUDY IS EXPECTED TO ENROLL A TOTAL OF APPROXIMATELY 400 TODDLERS.STUDY IS EXPECTED TO ENROLL ABOUT 400 TODDLERS AGES ONE TO THREE AT 35-50 CLINICAL TRIAL CENTERS IN THE UNITED STATES, EUROPE, AUSTRALIA AND CANADA.  Full Article

DBV Technologies Cash And Cash Equivalents Is At EUR 202.2 Million As Of June 30, 2018
Friday, 27 Jul 2018 

July 27 (Reuters) - Dbv Technologies Sa ::CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2018, WERE EUR 202.2 MILLION, COMPARED TO EUR 137.9 MILLION AS OF DECEMBER 31, 2017.  Full Article

DBV Technologies: Closing Of Underwriters' Option To Purchase Additional Shares In Global Offering
Monday, 26 Mar 2018 

March 26 (Reuters) - DBV TECHNOLOGIES SA ::REG-DBV TECHNOLOGIES ANNOUNCES CLOSING OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES IN GLOBAL OFFERING.FOLLOWING OPTION CLOSING, GROSS PROCEEDS TO COMPANY FROM GLOBAL OFFERING ARE APPROXIMATELY $172.5 MILLION.  Full Article

DBV Technologies ‍Announces Intention To Issue And Sell Up To $150 Mln Of New Ordinary Shares​
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Dbv Technologies Sa ::DBV TECHNOLOGIES ANNOUNCES THE LAUNCH OF A PROPOSED GLOBAL OFFERING OF ORDINARY SHARES, WHICH MAY BE IN THE FORM OF AMERICAN DEPOSITARY SHARES.DBV TECHNOLOGIES SA - ‍ANNOUNCED INTENTION TO ISSUE AND SELL UP TO $150.0 MILLION OF NEW ORDINARY SHARES​.DBV TECHNOLOGIES SA - ‍PLANS TO USE NET PROCEEDS FROM GLOBAL OFFERING TO FUND DEVELOPMENT AND COMMERCIALIZATION OF VIASKIN PEANUT, OTHERS ​.  Full Article

BRIEF-DBV Technologies FY Net Loss Widens To 166.1 Million Euros

* REPORTED ON TUESDAY FY SALES AND MARKETING EXPENSES EUR 32.2 MLN VS EUR 15.8 MLN YR AGO